📋 Tender Overview
The DAK-Gesundheit intends to conclude non-exclusive discount agreements for pharmaceuticals under the relevant legal provisions. This involves a formal procurement process for the active ingredient Elafibranor, ATC A05AX06, with interested pharmaceutical companies. The contracts will commence on December 1, 2026, and end on November 30, 2028, with provisions for all interested companies to enter into framework agreements under the same conditions during the contract period. Elafibranor, ATC A05AX06
